Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study will investigate if treatment results obtained with R-CHOEP in young high-risk
patients with diffuse large B-cell lymphoma can be further improved by the addition of
ibrutinib to this regimen.